The relationship between the use of combined hormonal contraception with a predominance of gestagens and the selected types of female body in young women from the region of Lower Silesia

Abstract Oral contraceptive agents are currently the most popular and one of the most effective methods for preventing pregnancy. The data shows that over 300 million women in the world use contraceptive drugs containing synthetic hormones to avoid an unwanted pregnancy. Their effects may affect other systems, leading to the occurrence of various problems associated with the use of the drug. The aim of the study is to estimate the frequency of prevalence of subjective effects associated with the use of combined hormonal contraception with a predominance of gestagens by young women Surveys were conducted among female students of Wrocław universities from December 2010 to January 2011. They covered 257 women aged statistically 23.58 (SD=2.95). They were divided into three age classes: 19-22, 23-24, 25-28. The individual age of menarche and the hormonal type of body were determined. Only persons with a gestagenic or estrogenic type of body were qualified for the study. Results: 64.6% of all respondents declared the use of hormonal contraception. Combined agents with a predominance of gestagens constituted 87% in this group. Their use brings both positive (90%) and negative (65%) aspects. The most common positive effects include high contraceptive effectiveness, regulation of menstruation and minimisation of skin problems. The most frequent negative effects include: weight gain, spotting, breast swelling and decreased libido. Surprisingly, the study did not show any correlation between the hormonal type and the occurrence of side effects. There was no significant statistical relationship between the type of hormonal contraception used and the hormonal type.

[1]  A. Nagle,et al.  Assessment of contraceptive needs in women undergoing bariatric surgery. , 2016, Contraception.

[2]  Kuldip Singh,et al.  Knowledge and factors determining choice of contraception among Singaporean women. , 2016, Singapore medical journal.

[3]  K. Morgan,et al.  A Qualitative Study of Prescription Contraception Use: The Perspectives of Users, General Practitioners and Pharmacists , 2015, PloS one.

[4]  Ø. Lidegaard The risk of arterial thrombosis increases with the use of combined oral contraceptives , 2015, Evidence-Based Medicine.

[5]  J. L. Bird,et al.  Gonadal Hormones are Associated with Body Shape and Symptoms of Disordered Eating in Women , 2015 .

[6]  V. Newton,et al.  Hormonal contraception and regulation of menstruation: a study of young women's attitudes towards ‘having a period’ , 2014, Journal of Family Planning and Reproductive Health Care.

[7]  A. Saki,et al.  Evaluating the Relationship between Body Size and Body Shape with the Risk of Breast Cancer. , 2013, Oman medical journal.

[8]  V. Hasselblad,et al.  Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[9]  M. Goldust,et al.  Risk factors of coronary artery disease in women. , 2013, Pakistan journal of biological sciences : PJBS.

[10]  G. Stabile,et al.  Effects of hormonal contraception on vaginal flora. , 2012, Contraception.

[11]  C. Matthews,et al.  Body Size in Relation to Urinary Estrogens and Estrogen Metabolites (EM) Among Premenopausal Women during the Luteal Phase , 2012, Hormones and Cancer.

[12]  E. Freeman,et al.  An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. , 2011, Contraception.

[13]  J. Dinger,et al.  Effectiveness of Oral Contraceptive Pills in a Large U.S. Cohort Comparing Progestogen and Regimen , 2011, Obstetrics and gynecology.

[14]  B. Tarlatzis,et al.  The use of hormonal contraception and its protective role against endometrial and ovarian cancer. , 2010, Best practice & research. Clinical obstetrics & gynaecology.

[15]  S. Delany-Moretlwe,et al.  Hormonal contraception and the risks of STI acquisition: results of a feasibility study to plan a future randomized trial. , 2008, Contraception.

[16]  H. Doll,et al.  The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol , 2007 .

[17]  K. Ginsburg,et al.  Menstrual irregularity from hormonal contraception: a cause of reproductive health concerns in minority adolescent young women. , 2006, Contraception.

[18]  M. Calderoni,et al.  Combined hormonal contraception. , 2005, Adolescent medicine clinics.

[19]  R. Burkman Clinical pearls: factors affecting reported contraceptive efficacy rates in clinical studies. , 2002, International journal of fertility and women's medicine.

[20]  H. Jernström,et al.  Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years. , 1997, American journal of epidemiology.

[21]  J. Condon,et al.  University students' subjective experiences of oral contraceptive use. , 1995, Journal of psychosomatic obstetrics and gynaecology.

[22]  H. Doll,et al.  The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. , 2007, Contraception.

[23]  F. Clavel-Chapelon,et al.  Several anthropometric measurements and breast cancer risk: results of the E3N cohort study , 2006, International Journal of Obesity.

[24]  A. Glasier Combined hormonal contraception , 2006 .

[25]  H. L. Shirley BIRTH CONTROL , 1932 .